MARKET

HURA

HURA

TuHURA Biosciences
NASDAQ
0.7495
-0.0072
-0.95%
After Hours: 0.7497 +0.0002 +0.03% 19:10 01/02 EST
OPEN
0.7700
PREV CLOSE
0.7567
HIGH
0.7973
LOW
0.7277
VOLUME
196.06K
TURNOVER
--
52 WEEK HIGH
5.50
52 WEEK LOW
0.7000
MARKET CAP
45.51M
P/E (TTM)
-0.4671
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at HURA last week (1222-1226)?
Weekly Report · 12/29/2025 10:29
Weekly Report: what happened at HURA last week (1215-1219)?
Weekly Report · 12/22/2025 10:29
Analysts Offer Insights on Healthcare Companies: Actinogen Medical (OtherATGGF) and TuHURA Biosciences (HURA)
TipRanks · 12/21/2025 22:40
TuHURA Biosciences announces release of Kintara’s CVR
TipRanks · 12/15/2025 13:06
TuHURA Biosciences Announces Kintara's REM-001 Trial Meets Primary Endpoint In Metastatic Cutaneous Breast Cancer
Benzinga · 12/15/2025 12:51
TuHURA Biosciences Reports REM-001 Meets Safety Endpoint in Metastatic Breast Cancer Trial
Reuters · 12/15/2025 12:50
Weekly Report: what happened at HURA last week (1208-1212)?
Weekly Report · 12/15/2025 10:37
TuHURA Biosciences Updates Portfolio Including VISTA Symposium In AML; $15.6M Financing Extends Runway For Key Phase 3 Milestones
Benzinga · 12/11/2025 12:39
More
About HURA
TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. Its lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It has initiated a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) compared to Keytruda plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. It is leveraging its Delta Opioid Receptor technology to develop bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. It is also focused on the novel VISTA inhibiting mAb, known as TBS-2025.

Webull offers TuHURA Biosciences Inc stock information, including NASDAQ: HURA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HURA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HURA stock methods without spending real money on the virtual paper trading platform.